Answers are grounded in this paper and cite their sources.
Shows divergent metabolic outcomes when combining sodium valproate with specific atypical antipsychotics in psychotic patients, indicating drug-dependent metabolic risk.
Aim: To investigate the metabolic effects of atypical antipsychotics with or without sodium valproate (VPA) supplementation Methods: The anthropometrics and metabolic markers were reviewed in 132 Japanese psychotic patients treated with olanzapine, paliperidone, or aripiprazole. The outcome values and triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratios reflecting insulin resistance were compared at baseline and at 3 and 6 months in VPA-non-using (-VPA) patients and VPA-using (+VPA) patients for each atypical antipsychotic.Results: There were significant increases relative to baseline in body mass index (BMI) at 6 months in olanzapine/-VPA patients, and higher TG levels at 6 months in olanzapine/-VPA patients, olanzapine/+ VPA patients, and paliperidone/-VPA patients. The TG/HDL-C ratio at 6 months was significantly higher in olanzapine/+VPA patients and olanzapine/-VPA patients. Aripiprazole had no significant effects on these markers irrespective of whether or not VPA was used.Conclusion: Sodium valproate may produce different metabolic effects on body weight, lipid levels, and insulin resistance when combined with various atypical antipsychotics.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: